AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery

Co-Founder & CEO Peter Fedichev describes why he believes reading the amino acid sequences that have been written into the human genome over time is a more realistic way of discovering small molecules that will work rather than via protein-target structure models. He also discovers how the company is leveraging this for its focus on aging conditions and longevity.